AbbVie announced a $2.1 billion acquisition of Capstan Therapeutics, gaining rights to a phase 1-stage in vivo CAR-T therapy targeting CD19 and Capstan’s proprietary targeted lipid nanoparticle (tLNP) delivery platform. The deal adds an early-phase candidate addressing autoimmune disorders and fibrosis to AbbVie’s pipeline, marking a substantial entry into in vivo CAR-T approaches. Capstan has raised significant venture funding and recently initiated its first clinical program.